Emergent Biosolutions Inc  

(Public, NYSE:EBS)   Watch this stock  
Find more results for EBS
35.20
+0.60 (1.73%)
After Hours: 35.20 0.00 (0.00%)
Feb 11, 4:02PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 34.03 - 35.60
52 week 26.36 - 40.49
Open 34.12
Vol / Avg. 573,962.00/454,381.00
Mkt cap 1.41B
P/E 37.35
Div/yield     -
EPS 0.94
Shares 38.94M
Beta 1.17
Inst. own 90%
Mar 7, 2016
Emergent BioSolutions Inc at Cowen Health Care Conference Add to calendar
Feb 25, 2016
Q4 2015 Emergent BioSolutions Inc Earnings Release - Tentative - 4:00PM EST - Add to calendar
Feb 23, 2016
Emergent BioSolutions Inc at RBC Capital Markets Healthcare Conference - 3:05PM EST - Add to calendar
Feb 22, 2016
Emergent BioSolutions Inc at Wells Fargo Specialty and Generic Drug Summit Add to calendar
Jan 11, 2016
Emergent BioSolutions Inc at JPMorgan Healthcare Conference (Q&A Session) - Webcast
Jan 11, 2016
Emergent BioSolutions Inc at JPMorgan Healthcare Conference - Webcast
Jan 11, 2016
Preliminary 2015 Emergent BioSolutions Inc Earnings Release
Dec 1, 2015
Emergent BioSolutions Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 19, 2015
Emergent BioSolutions Inc at Three Part Advisors Southwest IDEAS Investor Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 22.40% 8.16%
Operating margin 32.14% 12.90%
EBITD margin - 20.11%
Return on average assets 15.44% 4.67%
Return on average equity 25.38% 7.05%
Employees 1,280 -
CDP Score - -

Address

400 Professional Dr Ste 400
GAITHERSBURG, MD 20879-3457
United States - Map
+1-240-6313200 (Phone)
+1-240-6313203 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Company's two operating divisions include Biodefense and Biosciences. The Company's Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) threats. The Biodefense division's marketed products are BioThrax; BAT; Anthrasil; VIGIV, and RSDL. The Biodefense division investigational stage product candidates include NuThrax, PreviThrax, GC-072 and other biodefense product candidates. The Biosciences division's marketed products are WinRho SDF, HepaGam B, VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY, ES414 and otlertuzumab.

Officers and directors

Fuad El-Hibri Executive Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Daniel J Abdun-Nabi President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Robert G. Kramer Sr. Executive Vice President - Corporate Services Division, Chief Financial Officer and Treasurer
Age: 57
Bio & Compensation  - Reuters
Adam Havey Executive Vice President and President - BioDefense Division
Age: 44
Bio & Compensation  - Reuters
Ronald B. Richard Lead Independent Director
Age: 59
Bio & Compensation  - Reuters
Sue Bailey M.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Zsolt Harsanyi Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Jerome M. Hauer Independent Director
Age: 63
Bio & Compensation  - Reuters
George A. Joulwan USA Independent Director
Age: 75
Bio & Compensation  - Reuters